ImageneBio (IMA) Other Non-Current Assets (2020 - 2025)
ImageneBio (IMA) posted Other Non-Current Assets of $4.9 million for Q4 2025, down 1.49% sequentially from $5.0 million in Q3 2025, and up 378.7% YoY from $1.0 million in Q4 2024.
ImageneBio (IMA) Other Non-Current Assets (2020 - 2025) Analysis & Trends
ImageneBio has reported Other Non-Current Assets for 6 years, with the latest figure at $4.9 million in Q4 2025.
- Quarterly Other Non-Current Assets rose 378.7% year-over-year to $4.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.9 million (up 378.7% YoY) and the FY2025 annual result came in at $4.9 million, up 378.7% from the prior year.
- Other Non-Current Assets declined to $4.9 million in Q4 2025 per IMA's latest filing, from $5.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $24.2 million in Q2 2025 and troughed at $872000.0 in Q1 2021.
- A 5-year average of $4.6 million and a median of $3.4 million in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets plunged 81.16% in 2024, then soared 825.11% in 2025.
- Over 5 years, Other Non-Current Assets stood at $2.4 million in 2021, then soared by 58.8% to $3.8 million in 2022, then surged by 42.76% to $5.4 million in 2023, then slumped by 81.16% to $1.0 million in 2024, then surged by 378.7% to $4.9 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $4.9 million, $5.0 million, and $24.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - | 4.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.88 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Jun 30, 2025 | 24.17 Mn |
| Mar 31, 2025 | 10.23 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 5.51 Mn |
| Dec 31, 2023 | 5.41 Mn |
| Sep 30, 2023 | 4.08 Mn |
| Jun 30, 2023 | 3.67 Mn |
| Mar 31, 2023 | 3.18 Mn |
| Dec 31, 2022 | 3.79 Mn |
| Sep 30, 2022 | 3.79 Mn |
| Jun 30, 2022 | 3.18 Mn |
| Mar 31, 2022 | 3.18 Mn |
| Dec 31, 2021 | 2.39 Mn |
| Sep 30, 2021 | 872,000.00 |
| Jun 30, 2021 | 872,000.00 |
| Mar 31, 2021 | 872,000.00 |